Remi Vermeiren
Chairman, non-executive, independent director

Remi Vermeiren is the former managing director of KBC Bank (from 1989 to 1998) and chairman of KBC Bank and Insurance Company (from 1998 to 2003 when he retired). He has various board positions in other private and public companies such as Euronext and Crédit Commercial de France.

Jan Leemans, PhD
Non-executive, independent director

Jan Leemans is the former research director of Plant Genetic Systems in Ghent, Belgium. In the late nineties, he was member of the board of Hoechst Shering AgrEvo GmbH in Germany, of Nunza B.V. in the Netherlands and of the Flemish Institute of Biotechnology (VIB) in Belgium. He currently serves as a board member of CropDesign and of Maize Technologies International NV, of which he is also a co-founder.

Patrick Van Beneden
Non-executive director

Patrick Van Beneden is the executive vice-president of GIMV - Life Sciences, responsible for GIMV's investment portfolio in life sciences. Current board mandates include: Crop Design, Pamgene, I&I Gent, Avalon Pharmaceuticals, Psychiatric Genomics, TorreyPines Therapeutics, Xantos Biomedicine, Astex Technology, Biotech Fonds Vlaanderen and VZW FlandersBio. He is a member of the advisory board of Oxford Bioscience Partners and former board member of Innogenetics, Crucell and Pharming.

Alan Williamson, PhD
Non-executive, independent director

Alan Williamson is the former vice-president of basic research, immunology and inflammation and vice-president of research strategy at Merck US. He was a member of the advisory council of the NIH National Human Genome Institute from 1998 to 2002 and currently is a member of the Sequencing Advisory Panel and Hap Map Advisory Panel. He currently serves as a board member of several high tech companies, including Argenta Discovery, Oxxon Therapeutics, Onconova

Thierry Bogaert BVBA, represented by Dr. Thierry Bogaert, PhD
Founder, managing director, Chief Executive Officer (CEO)

Thierry Bogaert is a graduate form the Universtiy of Ghent and received an MSc degree form the University of Manitoba, Canada and a PhD from the Medical Research Council, Laboratory of Molecular Biology, Cambridge, United Kingdom. He held faculty positions at the MRC-LMB in Cambridge and the Medical Faculty of the University of Ghent. He founded Devgen in 1997 and has led the company since. He is actively involved with both the Crop Protection and Human Therapeutics businesses, having been instrumental in setting strategic direction and forging key collaborations in both areas that support the company goals and objectives.